Galderma, the world's largest pure-play dermatology company, reaffirms its position as a pioneer of world-first innovations across all product categories for 30 years. This journey ranges from Restylane (1996), the world's first hyaluronic acid dermal filler, to Restylane SHAYPE (2024), the world's first filler designed to deliver bone-mimicking structural support. The company also announced the opening of its new office in central Bangkok, underscoring its long-term commitment to the Thai market.
The opening ceremony of the new Thailand office was presided over by Mr. Choo Hon Keong, Head of JPAC. He outlined the company's direction under the mission that has guided Galderma for more than 45 years: "Advancing Dermatology for Every Skin Story - the global leader in comprehensive aesthetic and dermatological solutions for every skin." This reflects Galderma's commitment to leading with science, innovation and long-term consumer safety.
A pioneer, not a follower: 45 years of investment in dermatological science
Galderma was founded in 1981 through a partnership between two global leaders, L'Oreal and Nestle, with a single focus: skin - the body's largest organ. Over the past 45 years, Galderma has grown beyond a beauty brand into a specialized dermatology company offering comprehensive skin solutions, earning the trust of dermatologists worldwide for decades.
Galderma's leadership is not just a marketing claim. It is demonstrated by a track record of world's first innovations across all product categories over three decades:
- 1996 - Restylane, the world's first hyaluronic acid dermal filler.
- 1999 - Sculptra, the world's first biostimulator that induces the skin's own collagen production to address age-related dermal degeneration.
- 2020 - Restylane, the world's first hyaluronic acid dermal filler specifically developed for the lips.
- 2021 - Alluzience and Relfydess, the world's first ready-to-use liquid neuromodulators.
- 2024 - Restylane SHAYPE, the world's first filler engineered to provide bone-mimicking structural support.
These milestones reflect Galderma's unwavering commitment to ongoing investment in science and research, powered by a global R&D team of more than 640 experts who consistently bring new innovations to market. Their work ensures that Thai consumers can achieve results that look natural while maintaining long-term safety.
Long-term safety: "The heart behind every innovation"
For Galderma, safety does not end at the point of treatment. It extends across the entire consumer journey, in both the short and long term. Every Galderma product undergoes rigorous clinical evaluation, is supported by post-market surveillance, and is backed by real-world safety and efficacy data from more than 90 countries worldwide. This foundation of evidence has earned the trust of physicians and consumers for decades.
Guided by the belief that true beauty must go hand in hand with confidence in receiving "authentic, fresh and safe products at every treatment," Galderma is preparing to launch Thailand's first consumer-focused safety platform. Built around the simple concept of "Check Before You Inject," it encourages consumers to verify three key elements - doctor, clinic and product - before undergoing any injectable procedure. Details of the full platform and its features will be announced in the near future.
Integrated strategy across three business units: Complete skin health solutions
With its unique Integrated Dermatology Strategy, Galderma offers holistic skin health solutions through three core business units. This approach elevates dermatological and aesthetic science, supports sustainable growth with clinic partners, and strengthens Thailand's aesthetics industry over the long term.
- Injectable Aesthetics: A premium portfolio that includes hyaluronic acid dermal fillers, botulinum toxin products and regenerative biostimulators. This business is supported by GAIN (Galderma Aesthetic Injector Network), a global educational platform that focuses on sharing knowledge and advancing skills among healthcare professionals, thereby promoting higher standards and safety in aesthetic procedures.
- Dermatological Skincare: Led by Cetaphil(R), a trusted derma-skincare brand for sensitive skin that recently celebrated its 75th anniversary. Cetaphil continues to innovate with new formulations and products that respond to modern lifestyles and evolving skin needs.
- Therapeutic Dermatology: Focused on science-backed treatments for moderate-to-severe skin conditions, this business holds leading positions in multiple disease areas and continues to develop new therapeutic options to address unmet medical needs in dermatology.
Vision from Galderma's leadership
Mr. Choo Hon Keong, Head of JPAC, said: "The opening of our new office in Bangkok reflects Galderma's long-term commitment to Thailand. For 45 years, we have led the way with world-first aesthetic innovations across every product category, and we will continue to bring world-class science to Thai consumers, always putting their safety first."
Mr. Tawatchai Boontaveekit, General Manager, Galderma (Thailand) Co., Ltd., added: "We are committed to delivering the very best to Thai consumers - globally recognized innovations and international safety standards. Behind every natural, beautiful result lies decades of dermatological science and expertise. For us, true beauty means you can still recognize yourself."
Pharmacist Pirapat Sriwattanawong, Aesthetics Franchise Director, Galderma (Thailand) Co., Ltd., commented: "The real challenge for today's aesthetics industry is not only to drive sales, but to conduct business with standards and responsibility, always prioritizing the value and safety we deliver to consumers. That is why Galderma works closely with researchers, physicians and clinic partners to advance scientific knowledge, raise safety standards and help shape a more sustainable future for Thailand's aesthetics industry."